Business
NRx Pharmaceuticals Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI™ (Aviptadil-acetate) Trial in the Nation of Georgia
- Physicians in Georgia and Neighboring Countries will be Trained in Emergency Use of Intravenous ZYESAMI™ Under Agreement with Local Health Authorities - NRx
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"- Physicians in Georgia and Neighboring Countries will be Trained in Emergency Use of Intravenous ZYESAMI™ Under Agreement with Local Health Authorities\n - NRx Extends its Ongoing Phase 2/3 trial of Inhaled ZYESAMI™ to Georgia, in Partnership with Denk Pharma (Georgia), and Cromos, LLC\n - First Clinical Supplies Expected to Arrive in Georgia Within Two Weeks\n\n\nRADNOR, Pa., July 6, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical stage biopharmaceutical company, today announced it is initiating clinical training of Nation of Georgia (Georgia) ICU physicians, in the use of intravenous ZYESAMI™ (Aviptadil- acetate) for emergency use in patients suffering with Critical COVID-19, and inhaled ZYESAMI™ for use in phase 2/3 clinical trials, for patients suffering with COVID-19.\n\n \n \n \n \n \n \n\n \nNRx also announced that the ongoing phase 2/3 trial for the use of inhaled ZYESAMI™ has extended to Georgia, with the potential to also extend to neighboring countries in the Caucasus region, in partnership with Cromos, LLC and Denk Pharma (Georgia), operating as BriLife, LLC. NRx expects to ship clinical drug supplies to Georgia within two weeks. The development of intravenous Aviptadil-acetate, in non-GMP form was partially-funded by a collaboration agreement with Relief Therapeutics (SIX:RLF, OTCBB:RLFTF).\n\"We at NRx have been deeply touched by the warmth and hospitality extended by the people of Georgia, from the Prime Minister and the Minister of Health to the front-line doctors and nurses who are battling this lethal pandemic, that continues to rage despite great progress with vaccinations,\" said Prof. Jonathan C. Javitt, MD, MPH, Chairman and CEO of NRx. \"We look forward to our expanding partnership with Georgia and its people, a partnership supported by the US Congress through its funding of the Senator Richard G. Lugar Center for Public Health Research, at a time when the first lethal generations of Coronavirus (SARS and MERS) first threatened humanity. In the coming weeks, we hope to broaden this partnership in Georgia, as well as with our partners at the National Institutes of Health and elsewhere.\"\nAbout ZYESAMI™/VIP in COVID-19\nZYESAMI™ (Aviptadil-acetate) is a synthetic form of Vasoactive Intestinal Polypeptide (VIP) first discovered by the late Prof. Sami Said in 1970, and ZYESAMI™ is n...